ECSP10010401A - Paramyxovirus eficaz como antitumoral - Google Patents

Paramyxovirus eficaz como antitumoral

Info

Publication number
ECSP10010401A
ECSP10010401A EC2010010401A ECSP10010401A ECSP10010401A EC SP10010401 A ECSP10010401 A EC SP10010401A EC 2010010401 A EC2010010401 A EC 2010010401A EC SP10010401 A ECSP10010401 A EC SP10010401A EC SP10010401 A ECSP10010401 A EC SP10010401A
Authority
EC
Ecuador
Prior art keywords
virus
paramyxovirus
kill
antitumoral
effective
Prior art date
Application number
EC2010010401A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puehler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP10010401A publication Critical patent/ECSP10010401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapuera y virus Fer-de-Lance, los cuales pueden ser usados para la producción de un medicamento para el tratamiento de tumores. El virus tiene una selectividad para matar células tumorales humanas pero no para matar células diferenciadas normales humanas o en proliferación normal humanas con la misma dosis. Por medio de ingeniería genética, el virus se puede modificar de modo tal que se agreguen o reemplacen uno o más genes por los genes homólogos de un paramyxovirus relacionado. Por ese método, la actividad antitumoral del virus quimérico resultante se potencia en comparación con el virus parental.
EC2010010401A 2008-02-14 2010-08-12 Paramyxovirus eficaz como antitumoral ECSP10010401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
ECSP10010401A true ECSP10010401A (es) 2010-09-30

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010401A ECSP10010401A (es) 2008-02-14 2010-08-12 Paramyxovirus eficaz como antitumoral

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105331633A (zh) 2009-08-21 2016-02-17 梅里亚有限公司 重组禽副粘病毒疫苗及其制备和使用方法
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
JP5603486B2 (ja) * 2010-06-10 2014-10-08 インターベット インターナショナル ベー． フェー． 抗腫瘍組成物
MY173638A (en) * 2012-01-24 2020-02-12 Univ Georgia Parainfluenza virus 5 based vaccines
KR102310692B1 (ko) * 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
EP2292246A1 (en) * 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus

Also Published As

Publication number Publication date
AU2009214066A1 (en) 2009-08-20
EP2252307A2 (en) 2010-11-24
JP2011512344A (ja) 2011-04-21
EA201001266A1 (ru) 2011-04-29
KR20100122482A (ko) 2010-11-22
MX2010008942A (es) 2010-09-07
CA2715136A1 (en) 2009-08-20
CO6290694A2 (es) 2011-06-20
ZA201006561B (en) 2012-02-29
DOP2010000251A (es) 2010-08-31
BRPI0908365A2 (pt) 2015-08-11
CN101945660A (zh) 2011-01-12
US20090208495A1 (en) 2009-08-20
WO2009101149A3 (en) 2009-11-05
IL206860A0 (en) 2010-12-30
WO2009101149A2 (en) 2009-08-20
CR11631A (es) 2010-10-05

Similar Documents

Publication Publication Date Title
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CY1122275T1 (el) Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
MY168762A (en) Certain chemical entities, compositions and methods
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
EA201792092A1 (ru) Редактирование генов с использованием tat-индуцируемой crispr-эндонуклеазы
SG10201902574RA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
CU20170145A7 (es) Métodos para tratar infecciones por el virus filoviridae
MX375431B (es) Virus de la enfermedad de newcastle y usos de los mismos.
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
EA201590888A1 (ru) Мутации флавивирусного белка оболочки, нарушающие разборку вириона
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201391492A1 (ru) Соединения на основе микрорнк и способы модулирования активности mir-21
ECSP12011637A (es) Polipéptidos del factor ix modificados y usos de los mismos
NZ630596A (en) Methods for treatment of alport syndrome
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2015012471A (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização